ArticleCell research2020
A mouse model for SARS-CoV-2 infection by exogenous delivery of hACE2 using alphavirus replicon particles.
Abstract readLetter
In one paragraph
Article in Cell research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Prophylactic efficacy of an intranasal spray with 2 synergetic antibodies neutralizing Omicron.JCI insight · 2024Article
- SARS-CoV-2 immunity in animal models.Cellular & molecular immunology · 2024Review
- Review of selected animal models for respiratory coronavirus infection and its application in drug research.Journal of medical virology · 2022Review
- Multimeric RNAs for efficient RNA-based therapeutics and vaccines.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- UsingExpert opinion on drug discovery · 2022Article
- Immune responses to human respiratory coronaviruses infection in mouse models.Current opinion in virology · 2022Review
- Construction and evaluation of a self-replicative RNA vaccine against SARS-CoV-2 using yellow fever virus replicon.PloS one · 2022Article
- Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.Nature communications · 2021Article
- Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice.Signal transduction and targeted therapy · 2021Article
- ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker.Signal transduction and targeted therapy · 2021Article
- SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target.Cell research · 2021Article
- Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice.Fundamental research · 2021Review
- In Vitro and In Vivo Models for Studying SARS-CoV-2, the Etiological Agent Responsible for COVID-19 Pandemic.Viruses · 2021Review
- Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates.Frontiers in microbiology · 2021Review
- Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models.Emerging microbes & infections · 2020Article
- Role of neutrophil chemoattractant CXCL5 in SARS-CoV-2 infection-induced lung inflammatory innate immune response in anZoological research · 2020Article
- Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics.International immunopharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Ya-Nan Zhang *Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
Xiao-Dan Li *Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
Zhe-Rui Zhang *Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
Hong-Qing ZhangKey Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
Na LiKey Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
Jing LiuKey Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
Jia-Qi LiKey Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
Hua-Jun ZhangKey Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
Ze-Jun WangWuhan Institute of Biological Products Co. Ltd., No. 1 Huangjin Industrial Park Road, Jiangxia District, Wuhan, Hubei, 420115, China.
Shuo ShenWuhan Institute of Biological Products Co. Ltd., No. 1 Huangjin Industrial Park Road, Jiangxia District, Wuhan, Hubei, 420115, China.
Zheng-Li ShiKey Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.ORCID http://orcid.org/0000-0001-8089-163X
Hong-Ping WeiKey Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
Zhi-Ming YuanKey Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.ORCID http://orcid.org/0000-0002-3234-9616
Han-Qing YeKey Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China. yehq@wh.iov.cn.ORCID http://orcid.org/0000-0001-7770-4071
Bo ZhangKey Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China. zhangbo@wh.iov.cn.ORCID http://orcid.org/0000-0002-8895-3679
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Disease Models, AnimalRepliconAngiotensin-Converting Enzyme 2AnimalsBetacoronavirusCell Line, TransformedCoronavirus InfectionsCOVID-19Encephalitis Virus, Venezuelan EquineMiceMice, Inbred BALB CMice, Inbred C57BLPandemicsPeptidyl-Dipeptidase APneumonia, ViralSARS-CoV-2Ace2 protein, mouseAngiotensin-Converting Enzyme 2Peptidyl-Dipeptidase A
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.